drugset / Trial / NCT05573230
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
Non-randomizedSequentialOpen-labelBasic science
Summary
The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with cyclosporine in healthy participants. The study will also evaluate the safety and tolerability of LY3502970 in healthy participants. This study will last up to approximately 76 days for each participant.
Timeline
- Start
- 2022-10-17
- Primary completion
- 2023-01-17
- Completion
- 2023-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 200 mg | Oral |
| Subject | Orforglipron | Small molecule | 3 mg | Oral |
| Background | Midazolam | Small molecule | 200 ug | Oral |
Indications
No indication recorded.